Quidelortho Corp
F:QL1A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
First Capital Real Estate Investment Trust
TSX:FCR.UN
|
CA |
|
R
|
Reeder Teknoloji Sanayi ve Ticaret AS
IST:REEDR.E
|
TR |
Quidelortho Corp
Depreciation & Amortization
Quidelortho Corp
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Quidelortho Corp
F:QL1A
|
Depreciation & Amortization
$442m
|
CAGR 3-Years
16%
|
CAGR 5-Years
55%
|
CAGR 10-Years
34%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Depreciation & Amortization
$1.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Depreciation & Amortization
$156.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Depreciation & Amortization
$1.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Depreciation & Amortization
$3.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Depreciation & Amortization
$677.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Quidelortho Corp
Glance View
QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream. The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.
See Also
What is Quidelortho Corp's Depreciation & Amortization?
Depreciation & Amortization
442m
USD
Based on the financial report for Dec 28, 2025, Quidelortho Corp's Depreciation & Amortization amounts to 442m USD.
What is Quidelortho Corp's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
34%
Over the last year, the Depreciation & Amortization growth was -3%. The average annual Depreciation & Amortization growth rates for Quidelortho Corp have been 16% over the past three years , 55% over the past five years , and 34% over the past ten years .